CN105853384A - Azilsartan tablets and preparation method thereof - Google Patents
Azilsartan tablets and preparation method thereof Download PDFInfo
- Publication number
- CN105853384A CN105853384A CN201610415424.3A CN201610415424A CN105853384A CN 105853384 A CN105853384 A CN 105853384A CN 201610415424 A CN201610415424 A CN 201610415424A CN 105853384 A CN105853384 A CN 105853384A
- Authority
- CN
- China
- Prior art keywords
- azilsartan
- preparation
- sheet
- low
- hydroxypropyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses azilsartan tablets and a preparation method thereof, and belongs to the field of pharmacy. For the azilsartan tablets, each azilsartan tablet is prepared from, by mass, 7.80%-16.30% of azilsartan, 59.78%-70.18% of lactose monohydrate, 15.00%-18.00% of microcrystalline cellulose, 1.15%-1.40% of hydroxypropyl methylcellulose (5cps), 2.20%-2.80% of low-substituted hydroxypropyl cellulose, 2.20%-2.80% of polyethylene glycol 6000 and 0.55%-0.85% of magnesium stearate. By means of a fluidized bed top-spraying granulation method, three processes of mixing, granulation and drying in a traditional technology are completed in one step, the production efficiency is improved, and the prepared granules are uniform in granule size and good in fluidity and compression formability; meanwhile, due to the fact that a disintegrating agent is added internally and externally, the problem that the azilsartan tablets disintegrate and dissolve slowly is solved.
Description
Technical field
The present invention relates to pharmaceutical field, disclose a kind of oral formulations containing Azilsartan, also disclose one
The preparation method that Azilsartan is pelletized.
Background technology
Azilsartan is the angiotensin ii receptor antagonist medicine of a treatment vascular hypertension, is used for controlling
Treat vascular hypertension, be also the currently the only angiotensin ii receptor antagonist (husky smooth class) being in late-stage clinical
Medicine.
Chinese: Azilsartan；English name: Azilsartan；Structural formula is as follows:
Since angiotensin ii receptor antagonist (husky smooth class) enters China market, it is always maintained at higher
Growing trend.From 1998 " losartan " (losartans) and " DAIWEN " (valsartan) two kinds
After China lists, other kinds also subsequently enter China.At present, sartans due to matter height high price,
Can't become popular prioritizing selection, but along with the rising of Prevalence of Hypertension, people to hypertension this
The raising of prevalent condition understanding and the growth of income, sartans increasingly receives publicity, and is expected to become
The leader in following domestic antihypertensive drug market.Azilsartan sheet by Japan Takeda Pharmaceutical Company Limited 2012
Year listing, compared with the most conventional similar hypertension therapeutic medicine valsartan and Olmesartan, its clinical stage
More remarkable treatment effect.
At present, use of the preparation of Azilsartan sheet makes the form of Solide dispersion tablets or the side of direct compression more
Method.CN103260605A discloses a kind of azilsartan solid dispersion and preparation method thereof and drug regimen
Thing, carrier material is selected from polyvidone, poloxamer, Polyethylene Glycol, hydroxypropyl cellulose, polyethylene glycol oxide；
CN 103933000A discloses a kind of Azilsartan tablet and preparation method thereof, containing micronized A Qisha
Smooth, Lactis Anhydrous 21AN, Lactis Anhydrous 24AN, disintegrating agent, lubricant, use direct compression technique pressure
System forms.Prepare solid dispersion operation more, loaded down with trivial details；Although direct powder compression operation is few, technique letter
Single, but the requirement to adjuvant and equipment is high.Additionally, Azilsartan is BCS 4 compounds, it has low
Dissolving, the characteristic of hyposmosis, the general disintegrate of prepared tablet or dissolution do not reach requirement.
Summary of the invention
It is an object of the invention to provide a kind of method that Azilsartan is pelletized, and low by interior additional disintegrating agent
Replacing the method that hydroxypropyl cellulose prepares Azilsartan sheet, this Azilsartan sheet content is uniform, disintegrate dissolution
Hurry up, 5min i.e. disintegratable is complete, and in the most representational dissolution medium, 30min dissolution reaches more than 95%,
And chemical stability is preferable.
In Azilsartan sheet of the present invention every, the mass percent of each component is as follows:
Preferably, the formula of Tablets, in every, the mass percent of each component is as follows:
As required, tablet can also be coated by the present invention, with a kind of coated tablet of preparation, preferred film
Garment piece.
The present invention also provides for the preparation method of Azilsartan sheet of the present invention, and the method comprises the following steps:
1) Azilsartan raw material being micronized to particle diameter D90 is 0-15 μm；
2) lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000, low-substituted hydroxypropyl cellulose cross 60-100
Mesh sieve；
3) preparation of binding agent: by hypromellose (5cps): 50% ethanol solution=5-8: 100 (W:
V) proportions becomes the solution of 5%-8%；Preferably, by hypromellose (5cps): 50%
Ethanol solution=6: the proportions of 100 (W: V) becomes the solution of 6%；
4) processed good Azilsartan, lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000 are pressed prescription
Amount is weighed, and low-substituted hydroxypropyl cellulose is weighed mixing by the recipe quantity of 50%；
Described recipe quantity is:
Preferably, described recipe quantity is:
Above-mentioned recipe quantity can also be according to the mass percent of each component in aforementioned described every.
5) putting in fluid bed by the supplementary material mixed, use top spray mode to pelletize, parameter is as follows:
Blower fan frequency (Hz): 25-30
Internal layer atomization (bar): 1.8-2.0
Outer layer atomization (bar): 2.3-2.6
Inlet temperature (DEG C): 70
Temperature of charge (DEG C): 45-50
Peristaltic pump rotating speed (rpm): 15-20
6) granule made is taken out low-substituted hydroxypropyl cellulose and the magnesium stearate mixing of addition other parts
Tabletting after uniformly.
Beneficial effect:
The method that the present inventor is pelletized by fluid bed top spray, by the mixing in traditional handicraft, pelletizes and is dried
Three operation one steps complete, and improve production efficiency, prepared grain graininess uniformly, mobility, be compressed into
Shape is good, also solves the problems such as the sticking that occurs in tableting processes simultaneously.
Select low-substituted hydroxypropyl cellulose as disintegrating agent, utilize it to have disintegrate and adhesion characteristic concurrently, easily press
Make the feature of type, solve the defect that after fluidized-bed spray granulation, tabletting hardness is inadequate, friability is poor,
The hardness of tablet and the brightness of outward appearance can be improved；Use inside and outside interpolation low-substituted hydroxypropyl cellulose simultaneously
Mode, solve Azilsartan sheet disintegrate dissolution problem slowly, resulting in the A Qi of a kind of novelty
Sha Tan pelletizes and by the preparation method of interior additional disintegrating agent mixed pressuring plate.
Detailed description of the invention
Further illustrate the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
10mg tablet format:
Preparation method is as follows:
1) Azilsartan raw material is micronized to particle diameter D90≤15 μm；
2) lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000, low-substituted hydroxypropyl cellulose cross 80 mesh
Sieve；
3) preparation of binding agent: by hypromellose (5cps): 50% ethanol solution=5: 100 (W:
V) proportions becomes the solution of 5%；
4) processed good Azilsartan, lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000 are pressed prescription
Amount is weighed, and low-substituted hydroxypropyl cellulose is weighed mixing by the recipe quantity of 50%；
5) putting in fluid bed by the supplementary material mixed, use top spray mode to pelletize, parameter is as follows:
Blower fan frequency (Hz): 25-30
Internal layer atomization (bar): 1.8-2.0
Outer layer atomization (bar): 2.3-2.6
Inlet temperature (DEG C): 70
Temperature of charge (DEG C): 45-50
Peristaltic pump rotating speed (rpm): 15-20
6) granule made is taken out low-substituted hydroxypropyl cellulose and the magnesium stearate mixing of addition other parts
Tabletting after uniformly.
Embodiment 2
20mg tablet format:
Preparation method is as follows:
1) Azilsartan raw material is micronized to particle diameter D90≤15 μm；
2) lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000, low-substituted hydroxypropyl cellulose cross 80 mesh
Sieve；
3) preparation of binding agent: by hypromellose (5cps): 50% ethanol solution=6: 100 (W:
V) proportions becomes the solution of 6%；
4) processed good Azilsartan, lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000 are pressed prescription
Amount is weighed, and low-substituted hydroxypropyl cellulose is weighed mixing by the recipe quantity of 50%；
5) putting in fluid bed by the supplementary material mixed, use top spray mode to pelletize, parameter is as follows:
Blower fan frequency (Hz): 25-30
Internal layer atomization (bar): 1.8-2.0
Outer layer atomization (bar): 2.3-2.6
Inlet temperature (DEG C): 70
Temperature of charge (DEG C): 45-50
Peristaltic pump rotating speed (rpm): 15-20
6) granule made is taken out low-substituted hydroxypropyl cellulose and the magnesium stearate mixing of addition other parts
Tabletting after uniformly.
Embodiment 3
30mg tablet format:
Preparation method is as follows:
1) Azilsartan raw material is micronized to particle diameter D90≤15 μm；
2) lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000, low-substituted hydroxypropyl cellulose cross 80 mesh
Sieve；
3) preparation of binding agent: by hypromellose (5cps): 50% ethanol solution=8: 100 (W:
V) proportions becomes the solution of 8%；
4) processed good Azilsartan, lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000 are pressed prescription
Amount is weighed, and low-substituted hydroxypropyl cellulose is weighed mixing by the recipe quantity of 50%；
5) putting in fluid bed by the supplementary material mixed, use top spray mode to pelletize, parameter is as follows:
Blower fan frequency (Hz): 25-30
Internal layer atomization (bar): 1.8-2.0
Outer layer atomization (bar): 2.3-2.6
Inlet temperature (DEG C): 70
Temperature of charge (DEG C): 45-50
Peristaltic pump rotating speed (rpm): 15-20
6) granule made is taken out low-substituted hydroxypropyl cellulose and the magnesium stearate mixing of addition other parts
Tabletting after uniformly.
In GMP formulating plant, the Azilsartan sheet produced by the present invention, produce three batch samples continuously,
Its assay see table:
Table 1 Azilsartan sheet assay
Hardness test method: take 8, is measured and by defined according to YD-20KZ hardness tester rule of operation
Position place, measure respectively, hardness range controls at 15-20kgf.
Friability inspection technique: take sky weighing botle, accurately weighed weight, takes Azilsartan sheet (＞ 6.5g) and is placed in
In weighing botle accurately weighed, obtain the weight of test sample.According to FT-2000A1 friability instrument rule of operation,
Putting in cylinder by above-mentioned weighed test sample, starter rotates 100 times, after off-test, by test sample
Take out and check, fracture, crushing phenomenon must not occur, the test sample hair-dryer after test is blown away powder,
Putting in the most weighed above-mentioned empty weighing botle, accurately weighed, the difference of twice weighing is test sample less loss after test
Weight, less loss weight must not exceed 1%.
Content uniformity test: take test sample 10, according to content assaying method, measures each single respectively
Agent is with relative amount x that labelled amount is 100i, seek its averageWith standard deviation S and labelled amount and average it
The absolute value A (A=| 100-X |) of difference, if A+2.2S ＜ 15, then the content of test sample the most all meets rule
Fixed.
Disintegration inspection technique: by four general rules 0921 of " Chinese Pharmacopoeia " version in 2015, use lift disintegrate
Instrument, hangs on support by hanging basket by the stainless steel shaft of upper end, in leaching people's 1000ml beaker, and regulates hanging basket
When position makes it drop to low spot, screen cloth fills temperature in beaker bottom 25mm, beaker is 37 DEG C ± 1 DEG C
Water, regulation height of water level make hanging basket rise to during high point screen cloth is at the 15mm of underwater, hanging basket top can not be soaked
Not in solution.Take test sample 6, put in the glass tubing of above-mentioned hanging basket respectively, start disintegration tester and check,
Each all should whole disintegrates in 15 minutes.If any 1 can not disintegrate completely, should separately take 6 retrials, all should accord with
Close regulation.
Dissolution determination method: take this product, according to dissolution method (Chinese Pharmacopoeia version in 2015 the 4th
0931 second method), with pH4.5 (containing 0.5% sodium lauryl sulphate) solution 1000ml as dissolution medium,
Rotating speed is 75 turns per minute, operates in accordance with the law, and operation 30min takes solution 2ml and is centrifuged, and supernatant is as examination
Product solution, HPLC measures.Separately take Azilsartan reference substance about 10mg, accurately weighed, put 10ml measuring bottle
In, adding methanol and dissolve and be quantitatively diluted to scale, shake up, precision measures 1.0ml and puts in 100ml measuring bottle,
Add each dissolution medium and be diluted to scale, shake up, be measured in the same method, calculate the stripping quantity of every.
Conclusion: three batches of products all meet every quality standard, and repeatability is preferable, produces prescription process stabilizing reliable.
Study on the stability
Take Azilsartan sheet each influence factor: place 10 days under illumination, high temperature, super-humid conditions, and mould
Place 6 months under acceleration environment after intending listing packaging, the most periodically carry out product stability investigation, respectively investigate
Result see table:
Table 2 Azilsartan tablet stability investigates result
Conclusion: stability test result shows, each time point is investigated project and is all met regulation.
Above said content is only the basic explanation under present inventive concept, and according to technical scheme institute
Any equivalent transformation made, all should belong to protection scope of the present invention.
Claims (7)
1. an Azilsartan sheet, it is characterised in that: in every, the mass percent of each component is as follows:
Azilsartan sheet the most according to claim 1, it is characterised in that: the quality hundred of each component in every
Proportion by subtraction is as follows:
3. the preparation method according to claim 1 or 2 any one Azilsartan sheet, it is characterised in that:
Described preparation method comprises the following steps:
1) Azilsartan raw material being micronized to particle diameter D90 is 0-15 μm；
2) lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000, low-substituted hydroxypropyl cellulose cross 60-100
Mesh sieve；
3) preparation of binding agent: be by the volume ratio of the quality of hypromellose 5cps with 50% ethanol solution
The proportions of 5-8: 100 becomes the solution of 5%-8%；
4) by processed good Azilsartan, lactose monohydrate, microcrystalline Cellulose, polyethylene glycol 6000 by right
The percentage by weight requiring 1 or 2 is weighed, and low-substituted hydroxypropyl cellulose presses claim 1
Or 50% the weighing mixing of percentage by weight of 2；
5) supplementary material mixed is put in fluid bed, use top spray mode to pelletize；
6) granule that makes is taken out the weight ratio adding claim 1 or 2 50% low substituted hydroxy-propyl
After cellulose and magnesium stearate mix homogeneously, tabletting i.e. obtains Azilsartan sheet.
Preparation method the most according to claim 3, it is characterised in that: described step 3) system of binding agent
Standby by the proportions that volume ratio is 6: 100 of the quality of hypromellose 5cps Yu 50% ethanol solution
Become the solution of 6%.
Preparation method the most according to claim 3, it is characterised in that: described step 4) and step 6)
In weigh by following recipe quantity:
Preparation method the most according to claim 3, it is characterised in that: described step 4) and step 6)
In weigh by following recipe quantity:
Preparation method the most according to claim 3, it is characterised in that: described step 5) in top
Spray mode grain made parameter is as follows:
Blower fan frequency: 25-30Hz
Internal layer is atomized: 1.8-2.0bar
Outer layer is atomized: 2.3-2.6bar
Inlet temperature: 70 DEG C
Temperature of charge: 45-50 DEG C
Peristaltic pump rotating speed: 15-20rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415424.3A CN105853384A (en) | 2016-06-15 | 2016-06-15 | Azilsartan tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415424.3A CN105853384A (en) | 2016-06-15 | 2016-06-15 | Azilsartan tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853384A true CN105853384A (en) | 2016-08-17 |
Family
ID=56650367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610415424.3A Pending CN105853384A (en) | 2016-06-15 | 2016-06-15 | Azilsartan tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853384A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106333930A (en) * | 2016-09-28 | 2017-01-18 | 江苏中邦制药有限公司 | Azilsartan pellet tablet and preparation method thereof |
| CN106389428A (en) * | 2016-10-11 | 2017-02-15 | 上海现代制药股份有限公司 | Composition capable of improving Azilsartan bioavailability and stability and preparation method of composition |
| CN106983726A (en) * | 2017-05-18 | 2017-07-28 | 青岛正大海尔制药有限公司 | Azilsartan piece and preparation method thereof |
| CN112716907A (en) * | 2021-02-08 | 2021-04-30 | 浙江诺得药业有限公司 | Azilsartan tablets and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
| CN105030711A (en) * | 2015-09-11 | 2015-11-11 | 江苏中邦制药有限公司 | Preparation method of Azilsartan tablets |
-
2016
- 2016-06-15 CN CN201610415424.3A patent/CN105853384A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
| CN105030711A (en) * | 2015-09-11 | 2015-11-11 | 江苏中邦制药有限公司 | Preparation method of Azilsartan tablets |
Non-Patent Citations (1)
| Title |
|---|
| 凌沛学 主编: "《药物制剂技术》", 31 May 2007, 北京：中国轻工业出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106333930A (en) * | 2016-09-28 | 2017-01-18 | 江苏中邦制药有限公司 | Azilsartan pellet tablet and preparation method thereof |
| CN106389428A (en) * | 2016-10-11 | 2017-02-15 | 上海现代制药股份有限公司 | Composition capable of improving Azilsartan bioavailability and stability and preparation method of composition |
| CN106389428B (en) * | 2016-10-11 | 2019-12-13 | 上海现代制药股份有限公司 | Composition capable of improving bioavailability and stability of azilsartan and preparation method thereof |
| CN106983726A (en) * | 2017-05-18 | 2017-07-28 | 青岛正大海尔制药有限公司 | Azilsartan piece and preparation method thereof |
| CN106983726B (en) * | 2017-05-18 | 2020-05-08 | 正大制药（青岛）有限公司 | Azilsartan tablets and preparation method thereof |
| CN112716907A (en) * | 2021-02-08 | 2021-04-30 | 浙江诺得药业有限公司 | Azilsartan tablets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105853384A (en) | Azilsartan tablets and preparation method thereof | |
| CN110403911A (en) | A kind of isosorbide mononitrate sustained release tablets and preparation method thereof | |
| CN110420192B (en) | Isosorbide mononitrate sustained-release tablet and preparation method thereof | |
| CN105769905B (en) | A kind of modified-release tablets of potassium chloride and preparation method thereof | |
| CN104208039B (en) | Naproxen esomeprazole enteric preparation and preparation method thereof | |
| CN103356498B (en) | Mosapride citrate sustained-release tablet | |
| CN107998097B (en) | A kind of tablet and preparation method thereof containing olmesartan medoxomil | |
| CN110279667A (en) | A kind of tablets of vacyclovir hydrochloride and preparation method thereof | |
| CN105055350B (en) | A kind of preparation method of the tablet containing proton pump inhibitor | |
| CN113116840B (en) | Preparation method of hydroxychloroquine sulfate tablet | |
| CN113209036B (en) | Azilsartan tablets and preparation method and application thereof | |
| CN112023056B (en) | Fluconazole pharmaceutical composition and preparation method thereof | |
| CN112641750A (en) | Paroxetine hydrochloride tablet and preparation method thereof | |
| CN108066300A (en) | A kind of glipizide tablet and preparation method thereof | |
| CN112704668A (en) | Pramipexole dihydrochloride sustained-release composition | |
| CN103432090B (en) | Cyclovirobuxine D sublingual tablet as well as preparation method and application thereof | |
| CN105596341A (en) | Succinic acid trelagliptin solid preparation and preparation method thereof | |
| CN106580909B (en) | Solid pharmaceutical composition containing sarpogrelate hydrochloride | |
| CN102784115B (en) | oral tablet containing iloperidone and preparation method thereof | |
| CN105106145A (en) | Everolimus tablet and preparation method thereof | |
| CN114099506B (en) | Pharmaceutical composition containing sorafenib | |
| CN111358795A (en) | Tofacitinib citrate preparation and preparation method thereof | |
| CN104548115B (en) | A kind of pharmaceutic adjuvant microcrystalline cellulose pellets capsule core and preparation method thereof | |
| CN113768894B (en) | Olmesartan medoxomil tablet and preparation method and application thereof | |
| CN102895213B (en) | Stable cefotiam hexetil hydrochloride composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160817 |